nach oben

Tumor Biology

Erschienen in:

16.01.2016 | Original Article

Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma

verfasst von: Wenwei Chen, Lihong Chen, Zhixiong Cai, Dong Liang, Bixing Zhao, Yongyi Zeng, Xiaolong Liu, Jingfeng Liu

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

The prognosis of hepatocellular carcinoma (HCC) after surgical resection remains unsatisfactory for the majority of HCC patients who developed early recurrence or metastasis. There is still a lack of reliable biomarkers that can be used to predict the possibility of recurrence/metastasis in HCC patients after operation. In the current study, annexin A4, a calcium-dependent phospholipid-binding protein, has been found to be significantly elevated in HCC patients with early recurrence/metastasis, and had a strong correlation with portal vein tumor thrombosis (p = 0.03) and advanced BCLC stage (p = 0.002). Cox proportional hazards regression analysis revealed that annexin A4 was an independent prognostic predictor for both early recurrence/metastasis (HR = 1.519, p = 0.032) and overall survival (HR = 1.827, p = 0.009) after surgical resection. Meanwhile, Kaplan–Meier analysis showed that Patients with high-expression levels of annexin A4 had higher recurrence rate and shorter overall survival than those with low expression (log-rank test, p < 0.001). Furthermore, in vitro studies have demonstrated that overexpression of annexin A4 facilitated HCC cell migration and invasion via regulating epithelial–mesenchymal transition (EMT). In conclusion, annexin A4 has played important roles in the progression of HCC, and might act as a potential prognostic biomarker for HCC.

Nur mit Berechtigung zugänglich

El–Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.CrossRefPubMed

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.CrossRefPubMed

W-q C, Zheng R-s, S-w Z, Li N, Zhao P, G-l L, et al. Report of incidence and mortality in China cancer registries, 2008. Chin J Cancer Res. 2012;24(3):171–80.CrossRef

Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology. 2011;54(3):757–9.CrossRefPubMed

Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–35.CrossRefPubMedPubMedCentral

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–7.CrossRefPubMed

Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82(2):331–71.CrossRefPubMed

Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6(6):449–61.CrossRefPubMed

Ortiz-Zapater E, Peiró S, Roda O, Corominas JM, Aguilar S, Ampurdanés C, et al. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol. 2007;170(5):1573–84.CrossRefPubMedPubMedCentral

10.

Babbin BA, Lee WY, Parkos CA, Winfree LM, Akyildiz A, Perretti M, et al. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem. 2006;281(28):19588–99.CrossRefPubMed

11.

Zhao P, Zhang W, Tang J, Ma XK, Dai JY, Li Y, et al. Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci. 2010;101(2):387–95.CrossRefPubMed

12.

de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, et al. Annexin A1 regulates TGF-β signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A. 2010;107(14):6340–5.CrossRefPubMedPubMedCentral

13.

Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, et al. Enhanced expression of the protein kinase substrate annexin I in human hepatocellular carcinoma. Hepatology. 1996;24(1):72–81.PubMed

14.

Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, Jian G, et al. Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol. 2008;33(6):1157–63.PubMed

15.

Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, et al. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog. 2013;54(8):598–607.CrossRefPubMed

16.

Guo W, Man X, Yuan H, Shi J, Xue J, Wu M, et al. Proteomic analysis on portal vein tumor thrombus-associated proteins for hepatocellular carcinoma. Zhonghua yi xue za zhi. 2007;87(30):2094–7.PubMed

17.

Liu S, Sun MZ, Tang JW, Wang Z, Sun C, Greenaway FT. High-performance liquid chromatography/nano-electrospray ionization tandem mass spectrometry, two-dimensional difference in-gel electrophoresis and gene microarray identification of lymphatic metastasis-associated biomarkers. Rapid Commun Mass Spectrom. 2008;22(20):3172–8.CrossRefPubMed

18.

Liu S-H, Lin C-Y, Peng S-Y, Jeng Y-M, Pan H-W, Lai P-L, et al. Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol. 2002;160(5):1831–7.CrossRefPubMedPubMedCentral

19.

Mussunoor S, Murray G. The role of annexins in tumour development and progression. J Pathol. 2008;216(2):131–40.CrossRefPubMed

20.

Dreier R, Schmid KW, Gerke V, Riehemann K. Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem Cell Biol. 1998;110(2):137–48.CrossRefPubMed

21.

Lin LL, Chen CN, Lin WC, Lee PH, Chang KJ, Lai YP, et al. Annexin A4: A novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. Proteomics Clin Appl. 2008;2(4):619–34.CrossRefPubMed

22.

Duncan R, Carpenter B, Main L, Telfer C, Murray G. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2008;98(2):426–33.CrossRefPubMed

23.

Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004;64(24):9018–26.CrossRefPubMed

24.

Deng S, Wang J, Hou L, Li J, Chen G, Jing B, et al. Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett. 2013;5(1):107–12.PubMed

25.

Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, et al. Enhanced expression of annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer. 2009;125(10):2316–22.CrossRefPubMed

26.

Han EK-H, Tahir S, Cherian S, Collins N, Ng S. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer. 2000;83(1):83–8.CrossRefPubMedPubMedCentral

27.

Yamashita T, Nagano K, Kanasaki S-I, Maeda Y, Furuya T, Inoue M. Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem Biophys Res Commun. 2012;421(1):140–4.CrossRefPubMed

28.

Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, et al. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. Int J Cancer. 2014;134(8):1796–809.CrossRefPubMed

29.

Choi CH, Sung CO, Kim H-J, Lee Y-Y, Song SY, Song T, et al. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. Hum Pathol. 2013;44(6):1017–23.CrossRefPubMed

30.

Zimmermann U, Balabanov S, Giebel J, Teller S, Junker H, Schmoll D, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004;209(1):111–8.CrossRefPubMed

31.

Mogami T, Yokota N, Asai-Sato M, Yamada R, Koizume S, Sakuma Y, et al. Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. PLoS ONE. 2013;8(11):e80359.CrossRefPubMedPubMedCentral

32.

Lu ZJ, Liu SY, Yao YQ, Zhou YJ, Zhang S, Dai L, et al. The effect of miR-7 on behavior and global protein expression in glioma cell lines. Electrophoresis. 2011;32(24):3612–20.CrossRefPubMed

33.

Lin L-L, Huang H-C, Juan H-F. Revealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arrays. PLoS ONE. 2012;7(9):e44615.CrossRefPubMedPubMedCentral

34.

Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol. 2003;162(1):255–61.CrossRefPubMedPubMedCentral

35.

Mozos A, Sole M, Miquel R, Petit A, Nadal A, Fernández PL. Usefulness and limitations of alpha-methylacyl-CoA racemase expression in the hepatobiliary system and pancreas: a wide tissue microarray analysis of normal and neoplastic epithelia. Anal Quant Cytol Histol. 2010;32(5):261–8.PubMed

36.

Toyama A, Suzuki A, Shimada T, Aoki C, Aoki Y, Umino Y, et al. Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci. 2012;103(4):747–55.CrossRefPubMed

37.

Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, Finkel G, et al. Ras p21 expression in the progression of breast cancer. Hum Pathol. 1987;18(12):1268–75.CrossRefPubMed

38.

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.CrossRefPubMedPubMedCentral

39.

Huang X, Zeng Y, Xing X, Zeng J, Gao Y, Cai Z, et al. Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proc Natl Acad Sci U S A. 2014;12:22.

40.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMed

41.

Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.CrossRefPubMed

42.

Kan H, Guo W, Huang Y, Liu D. MicroRNA-520g induces epithelial–mesenchymal transition and promotes metastasis of hepatocellular carcinoma by targeting SMAD7. FEBS Lett. 2015;589(1):102–9.CrossRefPubMed

43.

Wong T-S, Gao W, Chan JY-W. Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors. Biomed Res Int. 2014;2014:921564.PubMedPubMedCentral

44.

Zhang W, Shi X, Peng Y, Wu M, Zhang P, Xie R, et al. HIF-1α promotes epithelial-mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer. PLoS ONE. 2015;10(6):e0129603.CrossRefPubMedPubMedCentral

45.

Yuan D, Xia H, Zhang Y, Chen L, Leng W, Chen T, et al. P-Akt/miR-200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells. Int J Oncol. 2014;45(6):2430–8.PubMed

46.

Yun E, Baek S, Xie D, Tseng S, Dobin T, Hernandez E, et al. DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene. 2014;34(21):2741–52.CrossRefPubMed

Titel: Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma
verfasst von: Wenwei Chen
Lihong Chen
Zhixiong Cai
Dong Liang
Bixing Zhao
Yongyi Zeng
Xiaolong Liu
Jingfeng Liu
Publikationsdatum: 16.01.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4823-6

Springer Medizin

Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines

Is cholesterol a mediator of cold-induced cancer?

SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer

MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma

Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia

Involvement of CASP3 promoter polymorphism (−1337 C > G) in the development and progression of non-small cell lung cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie